We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceuticals and AstraZeneca have settled patent litigation with a licensing agreement that enables Teva to market and manufacture a generic version of AstraZeneca’s diabetes drug Byetta. Read More
A federal report found opioid spending in Part D Medicare coverage rose to $4.1 billion last year, representing a modest dip in annual spending growth. Read More
The second highest court in the land rejected Mylan’s requested rehearing in two patent lawsuits, leaving the company with few options for avoiding the cases. Read More
Senate Judiciary Committee members and generics makers Tuesday both sung the praises of a bill aimed at preventing branded drugmakers from restricting access to their products. Read More
The U.S. Supreme Court has asked the solicitor general to consider if a lower court erred in mandating that Novartis wait six months after approval of a biosimilar before going to market. Read More